Johan Widmark | 2022-11-11 08:00
Relaunch of food supplements in Q4’22
With the structural foundation in place, Simris is now on track to exploit the three most promising verticals in the microalgae and cyanobacteria space. In December, Simris will relaunch its microalgae-based Food Supplement products. This time, however, the capsules will contain twice the EPA and DHA compared to previous products, and even so they will be half the size – which makes them easier to swallow, an important factor for consumers when making a purchase decision. They will also have more efficient packaging and a more competitive price. The launch will begin with Amazon in the USA and Simris’ own web shop in Sweden before rolling out to new markets through e-commerce and pharmacies.
Three drivers for revenue growth in 2023
Over the past two years, the recently acquired Cyano Biotech had an average turnover of over EUR 0.5m and is expected to deliver an EBITDA in the region of EUR 100k in 2022. Combined with the relaunch of food supplements starting Q4 this year and a refined and expanded B2B offering in 2023, this lends support to our expectation of a sharp rise in revenues in 2023.
However, the relaunch of food supplements is likely to increase costs during launch phase Q4/Q1, while the optimized production of Fucoxanthin and new B2B business will impact revenues in Q2’23 at the earliest. Along with the lower-than-expected revenue in Q3’22, we’ve made a downwards revision of our sales forecast for FY 2022 and FY 2023 to SEK 6m (11) and 20m (30) respectively. In addition to the cash position at SEK 3.4m, Simris has access to a loan facility from The Brand Laboratories, a company associated with Simris’ chairman, Steven Schapera of EUR 1m (SEK ~11m) and an additional SEK 1m overdraft facility with the bank.
Significant revaluation potential
One of the challenges for Simris historically has been how to allocate its limited resources to best capitalize on all the various and highly dispersed business opportunities that come with owning a world class microalgae production facility. But now we’re getting a clearer view on how management plans to capture the best opportunities, with a clear plan and roadmap for each vertical, focusing on the most high-value opportunities in each field. This is also the strategy likely to produce the most value for shareholders in the long-term.
All in all, we continue to see a significant revaluation potential in Simris. With only a fraction of listed peer multiples, we find support for a fair value of SEK 170-230m in 12-24 months. This translates to 0.94 SEK and 1.28 SEK per share in 2023-2024. However, should Simris produce an ADC platform license deal this will boost potential even further.
This commissioned research report is for informational purposes only and is to be considered marketing communication. This research does not constitute investment advice and is not a solicitation to buy shares. Information provided here or on Emergers’ website emergers.se is not intended to be financial advice. This research shall not be construed as a recommendation or solicitation to invest in the companies described. Emergers cannot be held liable for either direct or indirect damages caused by decisions made on the basis of information in this analysis. Investors are encouraged to seek additional information as well as consult a financial advisor prior to any investment decision.
This material is not intended to be financial advice. This material has been commissioned by the Company in question and prepared and issued by Emergers, in consideration of a fee payable by the Company. Emergers charges a standard fee for the production and broad dissemination of a detailed note following by regular update notes. Fees are paid upfront in cash without recourse. Emergers may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.
Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained herein represent those of the research analyst at Emergers at the time of publication. The company has been given the opportunity to influence factual statements before publication, but forecasts, conclusions and valuation reasoning are Emergers’ own. Forward-looking information or statements contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.
Exclusion of Liability: To the fullest extent allowed by law, Emergers shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained in this material.
No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Emergers’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in this material may not be eligible for sale in all jurisdictions or to certain categories of investors. Investors are encouraged to seek additional information as well as consult a financial advisor prior to any investment decision.
Investment in securities mentioned: Emergers has a restrictive policy relating to personal dealing and conflicts of interest. Emergers does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Emergers may have a position in any or related securities mentioned in this report, subject to Emergers’ policies on personal dealing and conflicts of interest.
Copyright: Copyright 2023 Incirrata AB (Emergers)
This document is prepared and provided by Emergers for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.
This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the ”FPO”) (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.
This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.
Emergers relies upon the ”publishers’ exclusion” from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Emergers does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.